Adil Nawaz

Adil Nawaz

Auto-generated profile, based on publicly available information

Adil Nawaz

Khyber Medical College, Peshawar, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2026 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
ANAdil Nawaz
Adil Nawaz
MAMuhammad Abbas
Muhammad Abbas
ZRZayna Rehman
Zayna Rehman
SFSyeda Samia Fatima
Syeda Samia Fatima
EKEhtesham Khan
Ehtesham Khan
FAFarah Afridi
Farah Afridi

21 November 2025 in BMC Neurology
Verified
Journal Article
Open access
PDF file
ANAdil Nawaz
Adil Nawaz
ABArsalan Bakhtiyar
Arsalan Bakhtiyar
MKMuhammad Ibrahim Khan
Muhammad Ibrahim Khan
ESErum Siddiqui
Erum Siddiqui
EKElsa Khan
Elsa Khan
MTMuhammad Taha
Muhammad Taha
This meta-analysis synthesizes evidence from all available randomized trials and observational cohort studies evaluating the efficacy and safety of ocrelizumab compared to placebo or active comparator therapies. Ocrelizumab (OCR), a monoclonal antibody targeting CD20-positive B-cells, is a high-efficacy therapy for multiple sclerosis (MS). While pivotal trials demonstrate its efficacy in reducing relapses, its impact on disability progression and its safety profile in broader, real-world populations require further synthesis. This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420251012243). We searched PubMed, Embase, and Cochrane Central until August, 2025, for randomized controlled trials (RCTs) and observational studies comparing OCR to placebo or active comparators in adults with MS. Primary outcomes were relapse-related measures and confirmed disability progression (CDP); safety outcomes included infections and malignancies. Twenty-five studies (4 RCTs, 21 observational) were included. OCR was associated with a significant 25% reduction in relapse rates compared to placebo (RR 0.75, 95% CI 0.61–0.93, p = 0.01). However, no significant differences were observed for achieving No Evidence of Disease Activity (NEDA) (RR 1.11, p = 0.13) or CDP (RR 0.90, p = 0.49). Safety analyses revealed no increased risk of overall adverse events, serious infections, or malignancies with OCR. Considerable heterogeneity was observed for several outcomes. This study confirms OCR’s significant efficacy in reducing relapse rates and its manageable safety profile in MS. However, its benefits on composite endpoints like NEDA and on halting disability progression remain uncertain and variable, highlighting a need for long-term studies to better define its role in mitigating disease progression.

23 February 2026 in Clinical Case Reports
Verified
Journal Article
Open access
BABilal Aslam
Bilal Aslam
FFFaiza Farooq
Faiza Farooq
SRShafiq Ur Rahman
Shafiq Ur Rahman
FBFazeela Bibi
Fazeela Bibi
UAUmama Alam
Umama Alam
JIJibran Ikram
Jibran Ikram
Spinal tuberculosis, also known as Pott's disease, in children is a rare manifestation of extrapulmonary tuberculosis. The nonspecific clinical features, such as chronic abdominal pain, of extrapulmonary TB or spinal TB in children tend to delay diagnosis. We present the case of a 14‐year‐old girl who has been suffering from abdominal and backpain associated with spinal tuberculosis. This is a case study reporting on the treatment and outcome of a 14‐year‐old girl who presented with progressive lower abdominal and back pains for 6 months, accompanied by slight kyphotic deformity. The involvement in this case was multilevel dorsal vertebral destruction from D5 to D12, and both paravertebral and right psoas abscesses on the magnetic resonance imaging and thin‐section computed tomography scans were very suggestive of spinal tuberculosis. A biopsy during the operations was not done; the treatment strategy and the plan were based on the diagnosis made from the clinical presentation and imaging studies. The justification for not doing the biopsy when the clinical features and imaging became concordant with the diagnosis of spinal tuberculosis would mean giving less importance to the biopsy result. Clinical and radiological improvement was good, with some improvement in the angle from 38° to 22° and VAS score for pain from 8/10 to 2/10 after 6 months. The treatment plan consisted of posterior surgical decompression and stabilization with anti‐tubercular therapy for 12 months. This particular case underscores the fact that tuberculosis of the spine can have a presenting symptom of chronic abdominal pain in children. Radiographic assessment plays a pivotal role when histologic confirmation is impossible initially, and prompt multidisciplinary care, including radiology and anti‐tuberculosis treatment, prevents catastrophic consequences.

16 November 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMansoor Khalid
Mansoor Khalid
ANAdil Nawaz
Adil Nawaz
MKMuhammad F.I. Khan
Muhammad F.I. Khan
MAMuhammad M. Amjad
Muhammad M. Amjad
MKMuhammad H. Khattak
Muhammad H. Khattak
SMSohana Memon
Sohana Memon
The benefit of adding chemotherapy to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutated non–small-cell lung cancer (NSCLC) remains uncertain. We evaluated the efficacy and safety of EGFR-TKI plus chemotherapy versus EGFR-TKI monotherapy. PubMed, Embase, and the Cochrane Library were searched from inception to August 2026 for randomized controlled trials (RCTs) comparing first-line EGFR-TKI plus chemotherapy with EGFR-TKI monotherapy in adults with advanced EGFR-mutated NSCLC. Random-effects models were used to pool hazard ratios (HRs) and risk ratios (RRs) with 95% CIs. Subgroup, sensitivity, trial sequential analysis, and GRADE assessments were performed. Seven RCTs involving 2454 patients were included. Combination therapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53-0.77) and progression-free survival (HR: 0.54; 95% CI: 0.45-0.64) compared with EGFR-TKI monotherapy. Objective response rate was also higher with combination therapy (RR: 1.14; 95% CI: 1.07-1.20). However, combination therapy substantially increased treatment-related toxicity, particularly grade ≥3 and hematologic adverse events. Sensitivity analyses supported the robustness of the primary efficacy findings. Subgroup analyses demonstrated consistent OS and PFS benefits across EGFR-TKI generations. Adding chemotherapy to first-line EGFR-TKI therapy improves survival and tumor response in advanced EGFR-mutated NSCLC but increases treatment-related toxicity. These findings support combination therapy while highlighting the need to balance clinical benefit against treatment burden.